Physician profile
Amanda Moran
NPI 1992231039
$9,132.79
in general payments reported to CMS, 2019-2025
34 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 91% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $164 · 2021: $612 · 2022: $2,872 · 2023: $1,571 · 2024: $1,888 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,928.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,995.92 | 2021-2025 | |
| Lundbeck LLC | $1,201.48 | 2021-2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $827.14 | 2021-2025 | Xtampza, Belbuca |
| Teva Pharmaceuticals USA, INC. | $659.84 | 2021-2022 | |
| Pfizer INC. | $545.06 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $449.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.64 | 2022-2025 | Relistor |
| Janssen Pharmaceuticals, INC | $336.25 | 2019-2025 | Spravato |
| Allergan, INC. | $300.96 | 2019-2022 | |
| Amgen INC. | $284.16 | 2022 | |
| Neurocrine Biosciences, INC. | $235.64 | 2019-2022 | |
| Alkermes, INC. | $202.74 | 2019 | |
| Averitas Pharma INC. | $187.49 | 2024-2025 | Qutenza |
| Almatica Pharma LLC | $180.95 | 2022-2023 | Gralise |
| Lilly USA, LLC | $178.34 | 2022-2025 | Emgality, Reyvow |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $151.47 | 2022-2023 | Trintellix |
| Corium, LLC | $124.93 | 2022 | |
| Arbor Pharmaceuticals, INC. | $112.91 | 2022 | |
| Impel Pharmaceuticals INC. | $109.21 | 2023 | Trudhesa |
| Vertex Pharmaceuticals Incorporated | $100.34 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $87.85 | 2023-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $80.11 | 2023-2025 | Symbravo, Auvelity |
| Scilex Pharmaceuticals INC. | $79.80 | 2023-2024 | Ztlido |
| Merz Pharmaceuticals, LLC | $77.15 | 2024-2025 | Xeomin |
| Medtronic, INC. | $46.39 | 2023-2024 | Synchromedii |
| Tersera Therapeutics LLC | $37.86 | 2023-2024 | Prialt |
| Eisai INC. | $36.88 | 2021-2022 | |
| Boston Scientific Corporation | $36.20 | 2023-2025 | General - Pain Management |
| Upsher-Smith Laboratories LLC | $30.46 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $25.85 | 2022-2023 | Belsomra |
| Abbott Laboratories | $21.75 | 2024 | Proclaim |
| Grt US Holding, INC. | $13.88 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.53 | 2021 | |
| Hikma Pharmaceuticals USA | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.